In the news


Oct 30, 2023
Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer

Oct 30, 2023
Neuromod tech developer Cognito Therapeutics has a new CCO


Oct 27, 2023
Clinical Potential of Cognito’s Gamma Sensory Stimulation Device in Alzheimer Disease: Brett Vaughan


Oct 24, 2023
Cognito Therapeutics Presents Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety, Adherence and Durability of Treatment Benefits Over 18 Months


Oct 18, 2023
Cognito Therapeutics to Present Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety and Durability of Treatment Benefits Over 18 Months at CTAD 2023


Oct 17, 2023
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer


Jul 17, 2023
Cognito Therapeutics Presents New MRI Data Showing Non-Invasive Gamma Stimulation Therapy Reduces Brain Atrophy and Myelin Loss in Alzheimer’s Disease


Jun 26, 2023
Cognito Therapeutics Announces Scientific Presentations at the Alzheimer’s Association International Conference 2023


May 9, 2023
Neuroimmune Interactions: From Basic Mechanisms to Novel Therapeutic Directions


May 8, 2023
Cognito Therapeutics Announces Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting


Apr 27, 2023
epocrates and Cognito Therapeutics Join Forces to Deliver Video Messaging to Healthcare Professionals


Apr 17, 2023
Cognito Therapeutics Announces Key Medical and Technology Leadership Appointments as Late-Stage Neurotechnology Platform Advances


Apr 17, 2023
Cognito finds new medical, technology heads in BrainStorm, Philips alums


Apr 30, 2023
Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer’s Disease at AD/PD 2023

Mar 23, 2023
Neuro Startup Cognito Corrals $73M as Alzheimer’s Device Commences Key Test


Mar 22, 2023
Can light reset brainwaves to treat Alzheimer’s? This Boston startup has $73 million to find out.


Mar 22, 2023
Cognito beams up $73M for study of light-and-sound neuromod therapy to treat Alzheimer's


Mar 22, 2023
Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease


Feb 21, 2023
Cognito Therapeutics Announces First Patient Enrollment in US Pivotal Study HOPE


Jan 20, 2023
The promising new Alzheimer's drugs to watch — and the far-out ideas that could reshape how we treat the disease


Dec 1, 2022
Startup’s Headset to Treat Alzheimer’s Will Undergo Wide Trial With Patients


Nov 1, 2022
Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer’s Disease at 2022 CTAD Conference


Aug 3, 2022
Cognito's light-and-sound therapy slows brain tissue atrophy in Alzheimer's study


Aug 1, 2022
Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients


Jul 13, 2022
Cognito Therapeutics Announces Data Presentations at the Alzheimer’s Association International Conference 2022


May 9, 2022
Cognito Therapeutics Joins Digital Medicine Society’s (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Clinical Measures


May 2, 2022
Some health apps are able not just to diagnose diseases, but also to treat them


Apr 13, 2022
Gamma Sensory Stimulation Demonstrates Efficacy in Alzheimer Disease in New Analysis


Mar 31, 2022
With pharma still struggling in Alzheimer’s, health tech companies want a swing


Mar 14, 2022
Ushering in a New Class of Disease-Modifying DTx


Mar 11, 2022
Cognito Therapeutics, Aetion to partner on AI model that identifies AD patients


Mar 8, 2022
Cognito Therapeutics and Aetion Announce Partnership to Use Artificial Intelligence to Identify Rapidly Progressing Forms of Mild Cognitive Impairment and Alzheimer's Disease


Mar 7, 2022
Fierce Medtech Names Cognito Therapeutics as One of Its “Fierce 15” Med Tech Companies of 2021


Mar 7, 2022
Fierce Medtech's 2021 Fierce 15


Mar 3, 2022
Cognito Therapeutics Announces Presentations for Novel Therapeutic in Alzheimer’s Disease at the 2022 American Academy of Neurology (AAN) Conference


Mar 1, 2022
Cognito Therapeutics to Present Virtual Symposium “Predicting Alzheimer’s Disease Progression with Neurophysiological Markers” at 2022 AD/PD Conference


Jan 27, 2022
Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment


Dec 14, 2021
Cognito Therapeutics Appoints Jennifer Newberger as Head of Regulatory and Compliance


Dec 8, 2021
Digital Therapeutics Alliance Elects Cognito Therapeutics’ Everett Crosland to its Board of Directors


Sep 15, 2021
Cognito Therapeutics CEO Brent Vaughan to Speak at CODE Conference 2021


Sep 8, 2021
Cognito Therapeutics Announces Formation of Payor Advisory Board


Aug 4, 2021
Cognito Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2021


Jul 26, 2021
Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021


Jul 14, 2021
Cognito Therapeutics Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2021


Jul 6, 2021
Cognito Therapeutics Appoints Gerald Chan as Chairman of the Board


Jun 14, 2021
Cognito Therapeutics Initiates Studies in Down Syndrome Associated Alzheimer’s Disease


May 18, 2021
Cognito Therapeutics Appoints Everett Crosland as Chief Commercial Officer


May 5, 2021
Cognito Therapeutics Appoints Jonathan Lieber as Chief Financial Officer


Mar 17, 2021
Cognito Therapeutics to Advance Digital Therapeutic for Alzheimer’s into Pivotal Studies Based on Positive Clinical Results Announced at AD/PD 2021


Mar 9, 2021
Cognito Therapeutics Announces Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer’s Disease


Mar 2, 2021
Cognito Therapeutics to Announce New Clinical Data Evaluating Gamma Frequency Neuromodulation to Treat Alzheimer’s Disease at 2021 AD/PD Virtual Conference


Jan 27, 2021
Cognito Therapeutics Appoints Mark Day, Ph.D., as Chief Business Officer


Jan 12, 2021
Cognito Therapeutics Receives FDA Breakthrough Device Designation for Next-Generation Digital Therapeutic in Alzheimer’s Disease


Dec 19, 2020